BRNS Barinthus Biotherapeutics plc.

Nasdaq www.barinthusbio.com


$ 1.34 $ -0.02 (-1.33 %)    

Friday, 17-Oct-2025 15:51:34 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 1.332
$ 1.30
$ 1.20 x 5
$ 1.51 x 2
$ 1.23 - $ 1.50
$ 0.64 - $ 2.92
171,605
na
54.24M
$ 0.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-20-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-24-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-25-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 06-14-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barinthus-biotherapeutics-and-clywedog-therapeutics-enters-into-a-definitive-all-stock-merger-agreement-to-form-combined-company-before-transaction-closes-the-combined-company-may-initiate-partial-tender-offer-to-purchase-up-to-27m-worth-of-its-outstanding-shares-held-by-barinthus-bio-shareholders

Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio"), an immunology and inflammation company focused on develo...

 barinthus-biotherapeutics-q2-eps-052-misses-033-estimate

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estim...

 barinthus-biotherapeutics-q1-eps-049-misses-036-estimate

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.49) per share which missed the analyst consensus estim...

 hc-wainwright--co-reiterates-buy-on-barinthus-biotherapeutics-maintains-3-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and maintains $3 price...

 barinthus-biotherapeutics-fy-2024-gaap-eps-155-beats-167-estimate-sales-1497m-inline

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(1.55) per share which beat the analyst consensus estimat...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION